Acute & Chronic Renal Failure Unit, Department of Clinical and Experimental Medicine, Parma University Hospital, Parma, Italy.
Acute & Chronic Renal Failure Unit, Department of Clinical and Experimental Medicine, Parma University Hospital, Parma, Italy.
Clin Nutr. 2016 Apr;35(2):317-321. doi: 10.1016/j.clnu.2015.04.006. Epub 2015 Apr 12.
BACKGROUND & AIMS: Abnormalities of blood glucose (BG) concentration (hyper- and hypoglycemia), now referred to with the cumulative term of dysglycemia, are frequently observed in critically ill patients, and significantly affect their clinical outcome. Acute kidney injury (AKI) may further complicate glycemic control in the same clinical setting. This narrative review was aimed at describing the pathogenesis of hyper- and hypoglycemia in the intensive care unit (ICU), with special regard to patients with AKI. Moreover, the complex relationship between AKI, glycemic control, hypoglycemic risk, and outcomes was analyzed.
An extensive literature search was performed, in order to identify the relevant studies describing the epidemiology, pathogenesis, treatment and outcome of hypo- and hyperglycemia in critically ill patients with AKI.
Patients with AKI are at increased risk of both hyper-and hypoglycemia. The available evidence does not support a protective effect on the kidney by glycemic control protocols employing Intensive Insulin Treatment (IIT), i.e. those aimed at maintaining normal BG concentrations (80-110 mg/dl). Recent guidelines taking into account the high risk for hypoglycemia associated with IIT protocols in critically ill patients, now suggest higher BG concentration targets (<180 mg/dl or 140-180 mg/dl) than those previously recommended (80-110 mg/dl). Notwithstanding the limited evidence available, it seems reasonable to extend these indications also to ICU patients with AKI.
血糖浓度异常(高血糖和低血糖),现在用累积术语“糖代谢紊乱”来表示,在危重病患者中经常观察到,并且显著影响他们的临床结果。急性肾损伤(AKI)可能在同一临床环境中进一步使血糖控制复杂化。本叙述性综述旨在描述重症监护病房(ICU)中高血糖和低血糖的发病机制,特别关注 AKI 患者。此外,还分析了 AKI、血糖控制、低血糖风险和结局之间的复杂关系。
进行了广泛的文献检索,以确定描述 AKI 危重病患者中低血糖和高血糖的流行病学、发病机制、治疗和结局的相关研究。
AKI 患者发生高血糖和低血糖的风险增加。现有证据不支持采用强化胰岛素治疗(IIT)的血糖控制方案对肾脏有保护作用,即那些旨在维持正常血糖浓度(80-110mg/dl)的方案。最近的指南考虑到 IIT 方案在危重病患者中与低血糖相关的高风险,现在建议将血糖浓度目标设定得更高(<180mg/dl 或 140-180mg/dl),高于之前推荐的目标(80-110mg/dl)。尽管可用的证据有限,但将这些指标扩展到 AKI 的 ICU 患者似乎是合理的。